Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 3,100 shares at $0.68 ($2K) on 2019-01-16, disclosed to the SEC on 2019-01-18.
Open-market purchase of $2k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.68 | 800 | $544 | 25.5% |
| 2 | $0.69 | 2,300 | $2K | 74.5% |
| Total | $0.69 avg | 3,100 | $2K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |